PMA device
Medtronic CoreValve Evolut R System
Medtronic, Inc. · Aortic Valve, Prosthesis, Percutaneously Delivered (NPT, Class III) · First FDA decision Jun 22, 2015, newest Oct 4, 2022Aortic stenosis
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
13
PMA pathway
Device trials
17
Naming "CoreValve Evolut R"
MAUDE reports
7
Brand "CoreValve Evolut R", since 2015
PubMed studies
109
Mentioning "CoreValve Evolut R"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Medtronic CoreValve Evolut R System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 6 of 13 decisions filed under this name.
- Medtronic CoreValve Evolut R System, Medtronic CoreValve Evolut PRO System, Medtronic Evolut PRO+ System, Medtronic EvolPMA supplement
P130021-S120 · Decided Oct 4, 2022 · 74 days after receipt · Normal 180 Day Track No User Fee
Device type: Aortic valve, prosthesis, percutaneously delivered (NPT) · Cardiology
5 more FDA decisions with a free account
Older decisions: P130021-S076, P130021-S073, P130021-S058, P130021-S051, P130021-S028, P130021-S025, P130021-S014
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Transcatheter Aortic Valve Replacement (TAVR)National analysisReview closedCAG-00430RUpdated Sep 23, 2026
- Transcatheter Aortic Valve Replacement (TAVR)National analysisReview closedCAG-00430NUpdated Sep 23, 2026
- Transcatheter Aortic Valve Replacement (TAVR) for Aortic Regurgitation (AR)National analysisUnder reviewCAG-00430R3Updated Sep 14, 2026
- Transcatheter Aortic Valve Replacement (TAVR)National analysisReview closedCAG-00430R2Updated Sep 10, 2026
- Transcatheter Aortic Valve Replacement (TAVR)National determinationOn the books20.32Updated Aug 16, 2023
Clinical trials
Device studies on ClinicalTrials.gov that name "CoreValve Evolut R", any status and sponsor, newest update first.
- Medtronic Evolut Transcatheter Aortic Valve Replacement in Low Risk PatientsPivotal-lookingActive, not recruiting
Medtronic CardiovascularPublic (MDT)
NCT02701283 · 2,223 participants · Start Mar 2016 · Primary completion Apr 2021
Device: Medtronic Transcatheter Aortic Valve Replacement Systems; Surgical Aortic Valve Replacement (SAVR) · For: Aortic Valve Stenosis
Sites: Phoenix, Arizona; La Jolla, California; Los Angeles, California · 87 sites in all
16 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "CoreValve Evolut R", and for the whole product code for context.
This brand
7 reports: 2 malfunction, 5 injury, 0 death
Whole product code NPT
77,669 reports: 12,243 malfunction, 57,723 injury, 7,693 death
Newest reports for this brand
MW5163840 · Received Dec 26, 2024 · Event dated Dec 12, 2024
Device type: Aortic Valve, Prosthesis, Percutaneously Delivered (NPT)
Patient problem as coded: Aortic Valve Insufficiency/ Regurgitation
4 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Medtronic Heart Valves Division
Z-0559-2021 · Started Oct 23, 2020
Reason given: Potential for Transcatheter Aortic Valve (TAV) leaflet damage when performing a post-implant balloon dilatation (PID).
Cause as FDA categorized it: Labeling design · Device type: Aortic Valve, Prosthesis, Percutaneously Delivered (NPT)
3 more recall records with a free account
Published research
The most relevant PubMed records for "CoreValve Evolut R"[tiab]. The summary above synthesizes these.
- Outcomes of Evolut R Versus CoreValve After Transcatheter Aortic Valve Implantation: A Meta-Analysis.
Sun Y, Li J, Fan R, et al. · Heart Lung Circ · 2020Comparative Study, Meta-Analysis
- Performance of the CoreValve Evolut R and PRO in Severely Calcified Anatomy: A Propensity Score Matched Analysis.
Piayda K, Hellhammer K, Veulemans V, et al. · Heart Lung Circ · 2020
- Medtronic CoreValve Evolut R with EnVeo R.
Sinning JM, Werner N, Nickenig G, et al. · EuroIntervention · 2013Research Support, Non-U.S. Gov't
- New Generation CoreValve Evolutࡊ R 23mm Aortic Valve Prosthesis: Initial Experience.
Muñoz-García AJ, Pascual I, Avanzas P, et al. · Rev Esp Cardiol (Engl Ed) · 2015Letter
- Direct aortic transcatheter aortic valve implantation.
Karaçağlar E, Akgün AN, Aydnalp A, et al. · Turk Kardiyol Dern Ars · 2021Case Reports
- Recapture failure in transcatheter aortic valve replacement with CoreValve Evolut R.
Ito N, Zen K, Kuwabara K, et al. · Catheter Cardiovasc Interv · 2021Case Reports
- Cost Utility of Transcatheter Aortic Valve Replacement: Sapien 3 Versus CoreValve Evolut R.
Posawatz D, Bloom J, Massed A, et al. · ASAIO J · 2023
- Patient-Specific Immersed Finite Element-Difference Model of Transcatheter Aortic Valve Replacement.
Brown JA, Lee JH, Smith MA, et al. · Ann Biomed Eng · 2023
- Reinterventions After CoreValve/Evolut Transcatheter or Surgical Aortic Valve Replacement for Treatment of Severe Aortic Stenosis.
Grubb KJ, Lisko JC, O'Hair D, et al. · JACC Cardiovasc Interv · 2024Research Support, Non-U.S. Gov't, Comparative Study
- Validation evidence with experimental and clinical data to establish credibility of TAVI patient-specific simulations.
Grossi B, Barati S, Ramella A, et al. · Comput Biol Med · 2024Validation Study, Research Support, Non-U.S. Gov't
- Thirty-day Outcome Following CoreValve Evolut R Transcatheter Aortic Valve Implantation: An All-comers Prospective Study.
Perrin N, Roffi M, Frei A, et al. · Rev Esp Cardiol (Engl Ed) · 2017
- Prosthetic valve endocarditis after transcatheter CoreValve Evolut R bioprosthesis implantation.
Zbroski K, Huczek Z, Sciso P, et al. · Postepy Kardiol Interwencyjnej · 2016
Other devices of this type
Also filed under product code NPT.
- Sapien 3 Transcatheter Heart Valve and AccessoriesEdwards Lifesciences, LLC · PMA 2025
- Edwards SAPIEN XT Transcatheter Heart ValveEdwards Lifesciences, LLC · PMA 2020
- Edwards SAPIEN 3 Ultra RESILIA Transcatheter Heart ValveEdwards Lifesciences, LLC · PMA 2026
- Medtronic CoreValve SystemMedtronic, Inc. · PMA 2023
- Edwards Sapien Transcatheter Heart Valve and Transfemoral and Transapical AccessoriesEdwards Lifesciences, LLC · PMA 2013
- Navitor Transcatheter Aortic Valve Implantation SystemAbbott Medical · PMA 2026
- Trilogy Transcatheter Heart Valve SystemJenaValve Technology, Inc. · PMA 2026
- LOTUS Edge Valve SystemBoston Scientific Corporation · PMA 2021
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.